Skip to main content

Participate in a Trial

Start your journey

NCT03805789 | Phase 2 | Interventional

Acute-graft-versus-host Disease

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

20 Sites
310 Participants
12 Years
NCT04262284 | Observational

Alpha-1 Antitrypsin Deficiency

Respreeza® Self-administration and Learning Program (AmAREtTI Study)

10 Sites
60 Participants
18 Years
NCT03744910 | Phase 3 | Interventional

Antibody-mediated Rejection

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

141 Sites
350 Participants
18 Years to 75 Years
NCT04082754 | Phase 1 | Interventional


A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

3 Sites
82 Participants
18 Years to 65 Years
NCT05485961 | Phase 2 | Interventional

Atherosclerotic Cardiovascular Disease

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

1 Sites
2310 Participants
18 Years
NCT04672733 | Observational

Chronic Inflammatory Demyelinating Polyneuropathy

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

17 Sites
100 Participants
18 Years
NCT05460234 | Observational

Chronic Kidney Disease

RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients

4 Sites
500 Participants
18 Years
NCT05524467 | Observational

Chronic Kidney Disease-associated Pruritus

Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients

61 Sites
4810 Participants
18 Years
NCT04044690 | Phase 3 | Interventional


A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

57 Sites
126 Participants
18 Years
NCT04167514 | Phase 3 | Interventional

Graft Versus Host Disease (GVHD)

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

25 Sites
136 Participants
12 Years
NCT05086575 | Observational

Haemophilia B

Observatory of Patients With Haemophilia B Treated by IdElvion®

25 Sites
100 Participants
NCT04864795 | Observational

Heart Failure

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

101 Sites
2000 Participants
18 Years
NCT05819775 | Phase 3 | Interventional

Hereditary Angioedema (HAE)

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

1 Sites
12 Participants
2 Years to 11 Years
NCT05875961 | Phase 1 | Interventional

Influenza, Human

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

3 Sites
600 Participants
18 Years
NCT03684018 | Phase 4 | Interventional

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Two Dose Levels of Privigen in Pediatric CIDP

5 Sites
30 Participants
2 Years to 17 Years
NCT04817670 | Phase 2 | Interventional

Sickle Cell Disease

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

22 Sites
24 Participants
18 Years to 60 Years
NCT05568888 | Phase 3 | Interventional

Traumatic Injury

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

29 Sites
8000 Participants
15 Years